Revenue
No reported data
Aldeyra Therapeutics, Inc. (ALDX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2021
2022
2023
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | $25.7M | $48.2M | $29.5M | $47.3M | $44.9M | $24.7M | $44.4M | $29.8M | $16.3M | $13.2M | $7.6M | $3.7M | $1.5M |
| Operating income | −$35.3M | −$60.1M | −$42.8M | −$62.7M | −$56.2M | −$36.4M | −$63.1M | −$39.7M | −$22.5M | −$18.7M | −$12.0M | −$7.3M | −$3.7M |
| Net income | −$33.8M | −$55.9M | −$37.5M | −$62.0M | −$57.8M | −$37.6M | −$60.8M | −$38.9M | −$22.3M | −$18.7M | −$12.1M | −$5.2M | $13.1M |
| Basic EPSper diluted share | -$0.56 | -$0.94 | -$0.64 | -$1.06 | -$1.07 | -$1.11 | -$2.24 | -$1.79 | -$1.40 | -$1.65 | -$1.40 | -$2.51 | $3.49 |
| Diluted EPSper diluted share | -$0.56 | -$0.94 | -$0.64 | -$1.06 | -$1.07 | -$1.11 | -$2.24 | -$1.79 | -$1.40 | -$1.65 | -$1.40 | -$3.09 | -$17.61 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 3, 2026Form 4 | Brady Todd CPresident and CEO | BuyCommon Stock | 250.0K | $1.67 | $417.5K | 1.72M |
| Mar 19, 2026Form 4 | DOUGLAS RICHARDDirector | BuyCommon Stock | 70.0K | $1.40 | $98.0K | 195.0K |
| Mar 18, 2026Form 4 | Alfieri MichaelPrincipal Financial Officer | BuyCommon Stock | 5.0K | $1.42 | $7.1K | 7.5K |
| Aug 13, 2025Form 4 | Alfieri MichaelPrincipal Financial Officer | BuyCommon Stock | 2.5K | $5.30 | $13.3K | 2.5K |
| Aug 11, 2025Form 4 | Machatha StephenChief Development Officer | SellCommon Stock | 22.1K | $5.15 | $113.7K | 221.8K |